Floatz logo

[14c]-a4250

Primary Biliary Cirrhosis

AlbireoPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Primary Biliary Cirrhosis cohort.

Asset / SponsorPhaseRating
URSODEOXYCHOLIC ACID
Xijing Hospital of Digestive Diseases
Phase 4A
Fenofibrate
Xijing Hospital of Digestive Diseases
Phase 3BB
Saroglitazar
Zydus Therapeutics Inc.
Phase 3BB
Obeticholic Acid
Intercept Pharmaceuticals
Phase 3BB
Mbx-8025
Gilead Sciences
Phase 3BB

View all 50 →

Same molecule, other indications

[14c]-a4250 is also rated in:

cholestasisDormant
CC
Indicative ·
47 / 100
View asset →
progressive familial intrahepatic cholestasisDormant
CC
Indicative ·
47 / 100
View asset →
Alagille syndromeDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →